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Abstract
Rhinocerebral mucormycosis is a rare disease, affecting almost
exclusively patients with known predisposing conditions such as
diabetes mellitus, immunocompromised status, haemochromato-
sis or major trauma. Subsequent to a case of rhinocerebral
mucormycosis in a 78-year-old woman without any known risk
factor, we reviewed the published English-language literature and
found an additional 72 cases. Reviewing all the published case
series of mucormycosis involving any site, the proportion of
apparently normal hosts among cases of rhinocerebral muco-
rmycosis was found to be 9.06% (95% conﬁdence interval 6.7–
11.8). These ﬁndings suggest that rhinocerebral mucormycosis in
patients without known predisposing factors is more prevalent
than was previously believed.
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Rhinocerebral mucormycosis, the most common presentation
of mucormycosis [1–3] is limited, in most cases, to people
with previously recognized risk factors such as diabetes
mellitus, immunosuppression, iron overload or after trauma
[1,4,5]. Subsequent to a fatal case of rhinocerebral mucormy-
cosis in a patient without known predisposing factors, we
reviewed the English-language literature for cases in appar-
ently normal hosts. In addition, we searched for all case ser-
ies of mucormycosis to determine the relative proportion of
patients without previously recognized predisposing condi-
tions among patients with rhinocerebral mucormycosis.
Case Report
A 78-year-old woman presented to the emergency room with
left palate pain and somnolence. The patient’s medical history
was remarkable only for hypertension, treated with hydrochlo-
rothiazide. The white blood cell count was 19 400 cells/lL, with
92% neutrophils and the serum sodium level was 106 mmol/L.
A loose tooth seen in the left upper jaw was removed,
intravenous normal saline and amoxicillin/clavulanic acid was
started and the patient’s condition improved signiﬁcantly.
On the fourth hospital day, right eye chemosis, ptosis and
lateral gaze palsy with central retinal artery thrombosis
appeared, followed by disarthria and right hemiparesis.
Magnetic resonance imaging of the brain revealed pansinusitis
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and a high signal in the left parietal cortex, compatible with
acute cerebral infarction. A lumbar puncture was performed.
The cerebrospinal ﬂuid contained 280 leukocytes/lL (124
neutrophils), with normal protein and glucose; the Gram
stain was negative. An orbital biopsy specimen obtained
during functional endoscopic sinus surgery, showed necrosis
of ﬁbroadipose tissue and hyphal elements within blood
vessel walls. The hyphae were broad, branching at right
angles without septations, consistent morphologically with
mucormycosis. Cultures obtained at operation yielded
Pseudomonas aeruginosa but were negative for fungal growth.
Liposomal amphotericin B and cefepime were begun but
the patient was comatose and expired 2 weeks later.
Literature review
We performed a MEDLINE search for articles published in
the English-language literature up to December 2007. The
search terms used were: zygomycosis, mucormycosis or
phycomycosis, as well as one of the terms: sinusitis, rhinoce-
rebral, rhino-orbito-cerebral or cerebral.
TABLE 1. Characteristics of patients suffering from
rhinocerebral mucormycosis, with no underlying predisposing
conditions (n = 73)
Characteristic n (%)
Mortality
n (%)
Age, mean ± SD (range) 41.5 ± 18 (0.17–82) –
Male : female ratio 2:1 26/8 (54/33)
Country
India 39 (53) 22 (56)
USA 15 (21) 8 (53)
Asia (other than India) 9 (12) 2 (22)
Europe and Israel 6 (8) 1 (17)
Other 4 (5) 1 (25)
Clinical presentation (applicable for 72/73; 99%)
Isolated sinus 27 (37) 8 (30)
Sino-orbital 13 (18) 4 (31)
Rhinocerebral 32 (44) 20 (63)
Positive culture (was done for 29/73; 40%)a 13/29 (45) –
Treatment (applicable for 55/73, 75%)
Surgery + antifungala 42 (76) 11 (26)
Antifungal aloneb 8 (15) 4 (50)
Surgery alone 5 (9) 2 (40)
Total death rate 34 (47)
aApophysomyces elegans, n = 6; Rhizopus species, n = 4; Mucor pusillus, Cunningha-
mella and Actinomucor elegans were described once.
bAntifungal, amphothricin B 47/50 (94 %) including four liposomal amphothricin B.
TABLE 2. Case series of patients
with rhinocerebral mucormycosis
Author (reference) Yeara Country Yearsb Cases
Number of patients
without predisposing
factors
Death rate
(%)
Addlestone and Baylin [7] 1975 USA 1964–1974 9 1 3/9 (33)
Pillsbury and Fisher [25] 1977 USA 1963–1977 13 1 2/13 (15)
Marchevsky et al. [43] 1980 USA 1958–1978 12 0 9/12 (75)
Blitzer et al. [44] 1980 USA 1972–1979 9 0 4/9 (44)
Centeno et al. [45] 1981 USA 5 years 10 1 6/10 (60)
Kurrasch et al. [46] 1982 USA 1970–1982 14 2 8/14 (57)
Maniglia et al. [47] 1982 USA 1977–1982 8 0 2/8 (25)
Ferry and Abedi [48] 1983 USA 1959–1981 16 1 11/16 (69)
Abedi et al. [49] 1984 USA 1957–1982 18 0 4/16 (25)
Rangel-Guerra et al. [50] 1985 Mexico 1970–1985 8 0 5/8 (62)
Parfrey NA [16] 1986 USA 1941–1983 14 2 6/13 (46)
Gamba et al. [51] 1986 USA 6 years 10 0 5/10 (50)
Ochi et al. [17] 1988 USA 6 years 11 2 9/11 (82)
Ferguson et al. [52] 1988 USA 1969–1988 12 0 6/12 (50)
Chetchotisakd et al. [53] 1991 Thailand 5 years 11 0 8/11 (73)
Nussbaum and Hall [54] 1994 USA 1979–1992 11 2 7/11 (64)
Shpitzer et al. 55] 1995 Israel 1981–1995 10 0 8/10 (80)
Rangel-Guerra et al. [56] 1996 Mexico 1980–1995 22 0 7/22 (32)
Peterson et al. [57] 1997 USA 1955–1995 28 1 8/28 (29)
Jiang and Hsu [58] 1999 China 1985–1997 15 0 6/15 (40)
Alobid et al. [59] 2001 Spain 1994–1999 5 0 0/5 (0)
Sohail et al. [60] 2001 Oman 8 years 9 0 3/9 (33)
Chakrabarti et al. [61] 2001 India 1990–1999 34 8 10/34 (29)
Talmi et al. [62] 2002 Israel 5 years 19 0 10/19 (53)
Petrikkos et al.[63] 2003 Greece 1993–2002 11 0 7/11 (64)
Nithyanandam et al. [64] 2003 India 1992–2000 34 0 16/34 (47)
Khor et al. [65] 2003 Taiwan 1988–2000 21 1 5/21 (24)
Dhiwakar et al. [33] 2003 India 1997–2000 8 1 6/8 (75)
Hosseini and Borghei[66] 2005 Iran 2000–2004 10 0 4/10 (40)
Safar et al. [67] 2005 Canada 1998–2003 7 0 4/7 (57)
Sundaram et al. [37] 2005 India 1971–2001 56 17 50/56 (89)
Al-Ajam et al. [68] 2006 Lebanon 1981–1999 12 0 7/12 (58)
Mohindra et al. [42] 2007 India 1997–2005 27 7 9/27 (33)
Cheema and Amin [69] 2007 Pakistan 4 years 5 0 2/5 (40)
Total 519 47c 257/519 (49.5)
aYear of publication.
bInclusion period.
cThe proportion of patients without predisposing factor is 9.06% (95% conﬁdence interval 6.7–11.8).
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All cases of patients with no predisposing factors (diabetes
mellitus; immune suppression; intravenous drug abuse; iron over-
load or deferoxamine treatment; s/p trauma recently in the same
area of mucormycosis infection): Cases included were those
with acute mucormycosis infection in the rhinocerebral
region diagnosed by histology with or without a positive cul-
ture, when no known predisposing conditions for rhinocere-
bral mucormycosis were reported and data regarding
outcome were available. Our search yielded a total of 73
cases including the present case [2,3,6–42] (Table 1).
Patients with no predisposing factors from case series: Our
search was limited to case series of all consecutive proven
mucormycosis infections in a deﬁned period, which included
cases of the rhinocerebral type. Series pertaining to oncolog-
ical medical centres only, were excluded. Our search yielded
34 case series meeting our criteria that included 519 patients
with rhinocerebral mucormycosis [7,16,17,25,33,37,42–69]
(Table 2). The overall mortality rate in these cases was
49.5% (49.3% in cases with predisposing factors). Forty-seven
out of 519 cases of rhinocerebral mucormycosis from these
case series (9.06%, 95% conﬁdence interval 6.7–11.8) were
found in patients without known underlying conditions for
mucormycosis.
Discussion
The agents of mucormycosis rarely cause disease as a result
of their low virulence potential. Undeﬁned defects of
macrophages and neutrophils present in diabetic and steroid-
treated patients, and deferoxamine treatment, allow replica-
tion of this mould [70]. The diagnosis was delayed in our
case of rhinocerebral mucormycosis because of the lack of
any known predisposing factors. Moreover, rhinocerebral
mucormycosis can occur without noticeable sinus involve-
ment, a presentation that could further delay the diagnosis.
Because a combination of urgent surgery and early adminis-
tration of an antifungal drug are crucial for possible cure,
delayed diagnosis frequently results in death.
In a literature review of 929 cases of all sites mucormycosis,
9.6% were found to have no predisposing factors, although
the data were not stratiﬁed according to the site of body
involved [1]. Most of the cases without risk factors in that
review (50%) were of the cutaneous form. In a 30-year liter-
ature review for pulmonary mucormycosis, 87 cases were
found, with 13% of them having no apparent underlying
illness [71]. In the current case series review, we found that
in rhinocerebral mucormycosis, the proportion of patients
without recognized predisposing factors is 9.06% (95% conﬁ-
dence interval 6.7–11.8). This is an unexpected high propor-
tion but it is consistent with the data of pulmonary
mucormycosis [71]. Although this proportion was extracted
from reported case series and could reﬂect a publication
bias, and no doubt case series are not representative of true
prevalence and incidence, rhinocerebral mucormycosis is not
common enough for adequate study designs and our esti-
mate is probably the best proxy available.
The mortality rate in the 73 patients with rhinocerebral
mucormycosis and without apparent known predisposing
conditions (47%) was similar to that found in the case series
review of overall rhinocerebral mucormycosis (49.5%). The
mortality rate was signiﬁcantly higher when the central ner-
vous system was involved compared to sinus or sino-orbital
involvement only (63% vs. 30% and 31%, respectively), as
also reported by others [1].
Seven patients in our review suffered from chronic sinusitis
or nasal polyps [6,15,19,27,30,39]. Four of these underwent a
nasal or sinus procedure prior to their illness and two addi-
tional patients underwent recent tooth extraction (four and
present case). These data might suggest that chronic sinusitis
and local surgery are additional risk factors for rhinocerebral
mucormycosis. The ﬁnding that the majority of cases
occurred in developing countries suggests that there may be
other predisposing conditions, such as malnutrition.
In summary, our review suggests that a considerable pro-
portion of rhinocerebral mucormycosis cases occur in
patients without previously recognized predisposing factors.
The characteristics and outcome of these patients are similar
to those occurring in patients with the known underlying
conditions. Whenever compatible clinical features for rhino-
cerebral mucormycosis are encountered, the absence of
predisposing factors should not be used to exclude this
dreadful disease, and maintaining a high index of suspicion
may lead to timely diagnosis and therapy.
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